CG200745   Click here for help

GtoPdb Ligand ID: 10055

Synonyms: CG-2 | CG-200745 | HDCG-0745
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: CG200745 is a pan-histone deacetylase inhibitor that is being developed by Crystal Genomics [3,7]. It is being explored for anti-tumourigenic [2-4,7] and anti-fibrotic potential [1,6].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 15
Topological polar surface area 90.9
Molecular weight 427.25
XLogP 3.23
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES ONC(=O)CCCCC=C(C(=O)NCCCN(C)C)COc1cccc2c1cccc2
Isomeric SMILES ONC(=O)CCCC/C=C(/C(=O)NCCCN(C)C)\COc1cccc2c1cccc2
InChI InChI=1S/C24H33N3O4/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28)/b20-11+
1. Choi HS, Song JH, Kim IJ, Joo SY, Eom GH, Kim I, Cha H, Cho JM, Ma SK, Kim SW et al.. (2018)
Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
Sci Rep, 8 (1): 11546. [PMID:30068917]
2. Chun SM, Lee JY, Choi J, Lee JH, Hwang JJ, Kim CS, Suh YA, Jang SJ. (2015)
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
PLoS ONE, 10 (3): e0119379. [PMID:25781604]
3. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS. (2012)
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Invest New Drugs, 30 (4): 1434-42. [PMID:21773733]
4. Jung DE, Park SB, Kim K, Kim C, Song SY. (2017)
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Sci Rep, 7 (1): 10921. [PMID:28883618]
5. Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, Cha H, Kwon SK, Ro S, Cho J et al.. (2015)
First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Invest New Drugs, 33 (5): 1048-57. [PMID:26076682]
6. Lee E, Song MJ, Lee HA, Kang SH, Kim M, Yang EK, Lee do Y, Ro S, Cho JM, Kim I. (2016)
Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.
Korean J Physiol Pharmacol, 20 (5): 477-85. [PMID:27610034]
7. Oh ET, Park MT, Choi BH, Ro S, Choi EK, Jeong SY, Park HJ. (2012)
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Invest New Drugs, 30 (2): 435-42. [PMID:20978925]